长效注射式多胞体脂质体 (DepoFoam®技术) 开发中的挑战
概括
使用DepoFoam®技术的多胞体脂质体,提供持续的药物递送,改善了半衰期. 尽管制造和复杂结构存在挑战,但正在进行的研究旨在增强其临床应用并克服开发障碍.
科学领域:
- 制药科学 制药科学
- 生物技术是生物技术.
- 材料科学 材料科学 材料科学
背景情况:
- 多胞体脂质体 (DepoFoam®技术) 是独特的基于脂质的持续释放药物递送系统.
- 它们的非重心结构使它们与其他脂质体类型区别开来,使它们能够产生大量的药物陷和可变的释放率.
研究的目的:
- 审查基于DepoFoam®技术的商业产品.
- 总结它们的结构,制造,释放特征,药理动力学和临床结果.
- 以突出挑战和未来的研究方向为多胞体脂质体.
主要方法:
- 经批准的商业产品的文献审查.
- 对DepoFoam®技术的组成,结构和制造工艺进行分析.
- 释放动力学,体内药理动力学和临床数据的评估.
主要成果:
- 德波 (DepoFoam®) 产品表现出持续释放,改善半衰期和多样化的负载能力.
- 已有成功的临床和商业应用,展示了该技术的潜力.
- 制造和结构的复杂性带来了重大发展挑战.
结论:
- 德波 (DepoFoam®) 技术为持续的药物输送提供了显著的优势.
- 克服制造和结构复杂性对于更广泛的应用至关重要.
- 持续的研究对于释放多胞体脂质体的全部潜力至关重要.
相关概念视频
Modified-Release Drug Delivery Systems: Overview
243
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
243
Modified-Release Drug Delivery Systems: Influencing Factors
216
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
216
Modified-Release Drug Delivery Systems: Drug Release Characteristics
265
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
265
Modified-Release Drug Delivery Systems: Rate-Programmed I
175
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
175
Site-Targeted Drug Delivery Systems: Polymeric Carriers
167
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
167
Oral Drug Delivery Systems: Delayed-Release Systems
229
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
229


